iRegene Therapeutics

iRegene Focuses on the Development of a New Generation of Chemically-Induced Cell Therapy ProductsiRegene is dedicated to providing innovative solutions for "incurable" diseases, such as Parkinson's disease and blindness, through the development of next-generation chemically-induced cell therapy products. As an expert in pure chemical induction for cell reprogramming, iRegene’s pure chemical induction system can easily reconstruct human cell types with high purity. iRegene is one of the earliest high-tech pharmaceutical companies in the world to focus on the research of efficient chemically-induced functional cell regeneration.Currently, iRegene has established a cell drug R&D technology platform based on small molecule chemical induction, centered around studying the regulatory mechanisms of cell fate and their translation into therapies. The company has implemented a comprehensive and systematic patent layout. iRegene has independently developed an AI-based platform for screening small molecule compounds to be used as inducers and culture medium in the development of multi-functional stem cell products, enabling the efficient transformation of induced pluripotent stem cells (iPSCs).Through extensive sequencing powered by AI technology, iRegene can analyze the differences between iPSCs and target transformed cells, identifying which genes determine the direction of cell differentiation and maturation—a critical issue often overlooked in the industry. Building on this platform, iRegene has further explored the use of small molecules to inhibit the development of the MHC pathway, establishing a world-leading universal cell induction platform.